Observed Signal · Aug 29, 2026 · Company Launch · Source: techcrunch · Impact: 2/5 · Sentiment: Neutral
Vijay Pande starts VZVC, making concentrated AI-biotech bets
Vijay Pande, formerly the head of life sciences at Andreessen Horowitz (a16z) who helped grow that practice to manage nearly $4 billion, left the firm and co-founded a much smaller venture firm, VZVC, with investor Zach Werner. VZVC plans to make a highly concentrated set of investments (roughly five per year), operates with no associates, and relies heavily on AI for daily operations. Pande discusses AI-driven advances in biology and chemistry, the limits posed by fragmented, proprietary biological datasets, and the promise of precision medicine and foundation models in biology. He remains involved with companies spun out of his lab, including Genesis Therapeutics, and cites Insitro as another notable AI-driven drug-discovery company.
Prominent investor launching a small, AI-driven VC focusing on biotech shifts a high-profile funding strategy and highlights issues around proprietary biological datasets; relevant to AI and VC communities but has limited immediate impact on the wider AdTech industry.
Track Andreessen Horowitz (a16z) Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Vijay Pande grew a16z’s life sciences practice into a practice managing close to $4 billion.
- Pande left a16z and co-founded a new firm, VZVC, with investor Zach Werner.
- VZVC is structured to make a small number of concentrated investments each year (around five) and operates without associates.
- VZVC relies heavily on AI for day-to-day operations.
- Pande is involved with Genesis Therapeutics and references Insitro as an AI-driven drug-discovery company.
Connected Companies & Entities
3 Entities mapped“Over the next decade-plus, he grew a16z’s bet into a practice managing close to $4 billion....”
“I look at someone like Antonio Gracias at Valor — he’s well-known now because of the SpaceX deal, but he’s been doing what he’s been doing f...”
“When you purchase through links in our articles, we may earn a small commission....”
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
VC Concentration, Inception Investing, Big AI Rounds
This enterprise IT/VC newsletter analyzes the growing concentration of venture capital, investment strategies for winning market share, and the accelerating shift toward agentic and domain-specific AI. It highlights that a16z raised $15B (about 18% of venture last year) and that four firms accounted for 40% of venture funding, arguing investors must specialize by stage or go big. The author describes boldstart’s focus on “Inception” rounds and Intuitive TAM, notes Fund VII at $250M and $15M inception checks for select founders, and celebrates Tres Finance’s $130M exit to Fireblocks led by boldstart. The piece also summarizes recent enterprise AI and security funding and M&A activity (e.g., Anthropic, Cyera, Observe, Koi, CrowdStrike/SGNL) and flags agentic AI, Physical AI in robotics, and execution/observability gaps as key infrastructure opportunities for 2026.
Vivodyne builds robotic labs to improve AI drug discovery
Vivodyne, a biotech startup spun out of the University of Pennsylvania, says the AI drug‑discovery field lacks the causal human biological data needed to train useful models and has built HIVE — modular robotic labs that grow human tissues, autonomously dose and monitor them, and generate longitudinal experimental data. The company claims its tissues achieve high concordance with human trial outcomes (e.g., liver 94%, airway 96%, bone marrow 100% on tested chemotherapies), has raised just under $80 million across two rounds led by Khosla Ventures, and last week opened what it calls the world’s largest “human data center” near San Francisco to scale throughput and feed AI research. Vivodyne positions its dataset as a way to enable causal, reinforcement‑learning style models for more predictive human biology and combination‑therapy design.
Insight Partners' Deven Parekh on Diversification Amid AI Concentration
In an interview at TechCrunch's StrictlyVC event, Insight Partners' co-leader Deven Parekh discussed the firm's diversified investment strategy, contrasting with rivals' heavy concentration in frontier AI labs like OpenAI and Anthropic. Parekh highlighted Insight's $90 billion in assets under management, its approach to early-stage investing, and its recent returns of over $20 billion to LPs. He noted that the firm holds stakes in both OpenAI and Anthropic, seeing them as complementary plays. Parekh also commented on the competitive landscape, losing the Legora deal to General Catalyst, and expressed caution on physical AI. He discussed the upcoming IPOs of Anthropic and OpenAI, the concentration risk in venture funding, and the importance of liquidity. The interview covered Insight's portfolio reviews, its investment in Armis, and its philosophy of letting performance speak rather than being loud on social media.
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.